Bluejay Diagnostics (BJDX) Other Non Operating Income (2020 - 2026)
Bluejay Diagnostics (BJDX) reported Other Non Operating Income of $731.0 for Q1 2026, down 89.06% on a YoY basis from $6681.0 in Q1 2025, and up 26.25% sequentially from $579.0 in Q4 2025.
Bluejay Diagnostics (BJDX) Other Non Operating Income (2020 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 7 years of Other Non Operating Income data on file, last reported at $731.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 89.06% year-over-year to $731.0; the trailing twelve-month figure through Mar 2026 stood at $1589.0 (down 97.39% YoY), and the FY2025 full-year result was $7769.0, down 93.98% from the prior year.
- Other Non Operating Income grew to $731.0 in Q1 2026, from $579.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $139729.0 in Q1 2023 to a low of -$80918.0 in Q4 2023.
- A 5-year average of $25986.1 and a median of $8566.0 in 2024 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income surged 204.3% in 2022 and sank 1759.18% in 2023, its largest moves.
- Tracing BJDX's Other Non Operating Income over 5 years: stood at $4877.0 in 2022, then slumped by 1759.18% to -$80918.0 in 2023, then soared by 118.23% to $14751.0 in 2024, then slumped by 96.07% to $579.0 in 2025, then increased by 26.25% to $731.0 in 2026.
- Business Quant data shows BJDX's Other Non Operating Income at $731.0 in Q1 2026, $579.0 in Q4 2025, and $554.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 731.00 |
| Dec 31, 2025 | 579.00 |
| Sep 30, 2025 | 554.00 |
| Jun 30, 2025 | -275.00 |
| Mar 31, 2025 | 6,681.00 |
| Dec 31, 2024 | 14,751.00 |
| Sep 30, 2024 | 8,566.00 |
| Jun 30, 2024 | 30,944.00 |
| Mar 31, 2024 | 69,549.00 |
| Dec 31, 2023 | -80,918.00 |
| Sep 30, 2023 | 43,235.00 |
| Jun 30, 2023 | 90,383.00 |
| Mar 31, 2023 | 139,729.00 |
| Dec 31, 2022 | 4,877.00 |
| Sep 30, 2022 | 60,406.00 |
| Dec 31, 2021 | -4,676.00 |
| Mar 31, 2021 | 6,111.00 |
| Dec 31, 2020 | 147,323.00 |
| Sep 30, 2020 | 4,344.00 |